This week, cannabis coverage focused on research limitations at Michigan universities, emerging science regarding cognition and use disorder stigma.
Friday, June 19, 2026 — top 2 across News, Studies, Policy, and Memes
This article reports the Drug Enforcement Administration will hold a rescheduling hearing featuring panelists seemingly selected for opposition to cannabis rescheduling.
In the Mix: 20 More Articles — June 19, 2026 →Michigan regulations prevent universities from researching dispensary-sourced cannabis on campus, leading Michigan State University to conduct mobile studies.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →This digest highlights recent observations regarding cannabis use trends in young adults, cognitive function following abstinence, and policy shifts in Bangkok.
CED Cannabis Science Digest: 3 Cannabis Use, Cognition, and Policy Signals Worth Watching →This study found personal familiarity with cannabis use and respondent age correlate with attitudes toward cannabis use disorder in adolescents and adults.
Stigma toward individuals with cannabis use disorder across age groups: associations with familiarity and sociodemographic characteristics. →This article reports the Drug Enforcement Administration will hold a rescheduling hearing featuring panelists seemingly selected for opposition to cannabis rescheduling.
In the Mix: 20 More Articles — June 19, 2026 →Michigan regulations prevent universities from researching dispensary-sourced cannabis on campus, leading Michigan State University to conduct mobile studies.
Michigan universities can’t study dispensary pot on campus. MSU went mobile →This article reports the Drug Enforcement Administration will hold a rescheduling hearing featuring panelists seemingly selected for opposition to cannabis rescheduling.
In the Mix: 20 More Articles — June 19, 2026 →Michigan regulations prevent universities from researching dispensary-sourced cannabis on campus, leading Michigan State University to conduct mobile studies.
Michigan universities can’t study dispensary pot on campus. MSU went mobile →Digest-Level Clinical Commentary
These digest items highlight a meaningful shift in cannabis research pragmatism, where institutional barriers are prompting investigators like those at Michigan State University to conduct real-world studies of actual dispensary products rather than waiting for idealized laboratory conditions, which should ultimately yield more clinically relevant data for practitioners like myself. The recurring emphasis on stigma reduction and familiarity as drivers of more rational attitudes toward cannabis use disorder suggests that our field’s credibility depends on continued evidence generation and destigmatization work in parallel, not sequentially. The relative scarcity of high-quality human clinical trial data on June 19, 2026 underscores that cannabis medicine remains evidence-limited in many domains, requiring ongoing humility in clinical recommendations and careful patient counseling about what we actually know versus what remains investigational.
These items reflect ongoing regulatory and practical constraints on cannabis research infrastructure, particularly around studying commercially available products in academic settings. The persistent stigma toward cannabis use disorder despite increased familiarity suggests that clinical acceptance and public perception remain disconnected, warranting continued attention to evidence-based education. The overall digest indicates that high-quality clinical trial data remains limited, with most cannabis-related coverage focusing on policy adaptations and epidemiological observations rather than robust efficacy or safety studies.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
